Shafer Michael D 4

What Happened

• Michael D. Shafer, Executive Vice President of Thermo Fisher Scientific (TMO), received equity awards reported on a Form 4 covering transactions on 2026-02-25. The filing shows three award entries totaling 18,396 shares: 1,569 shares (award), 3,129 shares (award), and 13,698 shares reported as a derivative award. All were reported with an acquisition price of $0.00 (typical for restricted stock units/options granted as compensation).

Key Details

• Transaction date(s): February 25, 2026; Form 4 filed February 27, 2026 (timely filing).
• Transaction type: A = Award/Grant (RSUs and a derivative award/option-like instrument).
• Shares acquired: 1,569; 3,129; and 13,698 (total = 18,396).
• Price: $0.00 per share (compensation grant).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Notable footnotes:
  • F1: One award is a performance-based restricted stock unit (granted Feb 19, 2025); the committee certified performance on Feb 25, 2026. One‑third vests Feb 28, 2026 and 2027; final third vests Feb 28, 2028 and is subject to upward/downward adjustment based on relative TSR (measurement period Jan 1, 2025–Dec 31, 2027).
  • F2: One entry reflects an adjustment to a prior (Feb 22, 2023) performance-based RSU tranche; the committee certified a 15% reduction for relative TSR, reducing the award by 56 shares.
  • F3: The derivative award vests in four equal annual installments beginning Feb 28, 2027 (i.e., it is not fully vested immediately).

Context

• These are compensation awards (not open-market purchases or sales) and thus reflect company pay and performance determinations rather than direct insider buying/selling. The derivative award’s vesting schedule and the TSR-based adjustments mean portions of the awards remain subject to future vesting and performance outcomes.